Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | NOS2 | P35228 | 4/20 | 0.53 |
| ▸ | NOS3 | P29474 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | INMT | O95050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12587871 | 0.84 | NOS3 (0.41) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL17215357 | 0.81 | CHRNB2 (0.40) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL809756 | 0.81 | CHRNB2 (0.40) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL8147596 | 0.81 | CHRNB2 (0.40) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL809794 | 0.81 | CHRNB2 (0.40) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL16591593 | 0.80 | NOS3 (0.37) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL24090168 | 0.79 | NOS3 (0.40) | NOS1NOS2NOS3 | |
| SCHEMBL810036 | 0.79 | NOS1 (0.35) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL809570 | 0.79 | NOS1 (0.36) | NOS1NOS2NOS3USP2INMT | |
| SCHEMBL6859100 | 0.77 | NOS3 (0.47) | NOS1NOS2NOS3USP2INMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024116032-A1 | LIGHT-EMITTING DEVICE | 株式会社半導体エネルギー研究所 | 2024-06-06 | — | — | WO | disclosed |
| EP-2968288-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9765074-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-2877471-B1 | SPIRO-FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160024091-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2968288-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9206198-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2877471-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20150099729-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2014150132-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018764-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099729-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NOS1 606/4885NOS2 1057/4885NOS3 1173/4885 |
| US-20160024091-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NOS1 620/4885NOS2 1093/4885NOS3 1239/4885 |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NOS1 606/4885NOS2 1057/4885NOS3 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.